Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-111 with Paclitaxel and Trastuzumab in HER2+ Gastroesophageal Cancers
NCT01774851Phase 2Terminated
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Jan 2013
- Primary completion
- Jul 2015
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MM-111 in esophageal cancer, gastroesophageal junction cancer and gastric cancer (GC) (2 arms), sponsored by Merrimack Pharmaceuticals. Primary endpoint: Progression Free Survival at 30 months. Started Jan 2013; status: terminated.
02
Drugs
MM-111
03
Conditions
esophageal cancergastroesophageal junction cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT01774851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01774851.